Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
D. J. Sheward, C. Kim, R. A. Ehling, A. Pankow, X. Castro Dopico, D. P. Martin, S. T. Reddy, J. Dillner, G. B. Karlsson Hedestam, J. Albert, B. Murrell
This study assesses neutralizing antibody responses against the SARS-CoV-2 Omicron variant, showing reduced potency compared to the pandemic founder but with some cross-neutralizing capacity in vaccinated individuals.
bioRxiv · Dec 19, 2021 · PreprintImmunology